Core Viewpoint - Sanofi anticipates a slight decline in vaccine sales for the year due to changes in U.S. policy, while aiming for high-single-digit overall sales growth by 2026 [1][2] Vaccine Sales - Vaccine sales are expected to be "slightly negative" this year, influenced by U.S. policy changes under President Trump and the impact of anti-vaccine sentiments [1] - CEO Paul Hudson acknowledged a dip in vaccine coverage rates due to public debates and emphasized the need to defend the positive impact of vaccines [2][3] Financial Performance - Sanofi's shares fell nearly 12% in 2025, underperforming the broader European sector index, and remained flat following the results announcement [4] - CFO François-Xavier Roger stated that the company cannot offset the loss of sales from Dupixent once it comes off patent, describing it as "too big to be mitigated" [4] Growth Strategy - Sanofi is focused on cushioning the impact on earnings per share through existing products, new launches expected through 2031, and strategic external acquisitions [5] - The company’s largest deal in 2025 was a $9.5 billion acquisition of Blueprint Medicines, which added Ayvakit to its portfolio [6]

Core Insights - GSK plc is a significant player in the global vaccine market, focusing on vaccines for various infectious diseases [1] Group 1: Vaccine Sales Performance - GSK's vaccine sales in the United States are declining, particularly for the shingles vaccine Shingrix and the RSV vaccine Arexvy, due to a challenging external environment [2] - In the first half of 2025, U.S. sales of Shingrix and Arexvy fell by 56% and 18% respectively, contributing to an overall 11% decline in total vaccine sales at constant exchange rates (CER) [4] - Despite slight improvements in the second quarter of 2025 due to higher sales in Europe, challenges in the U.S. and other international markets are expected to persist [5] Group 2: Regulatory Impact - Revised recommendations from the U.S. Advisory Committee on Immunization Practices (ACIP) in June 2024 have negatively impacted Arexvy's sales, limiting its use for adults aged 50-74 to those at increased risk of severe RSV disease [3][10] Group 3: Pipeline and Future Prospects - GSK has a promising pipeline, including the recently approved pentavalent meningococcal vaccine Penmenvy, which could enhance immunization schedules [6] - The company is also developing vaccines for measles, mumps, rubella, varicella, and various mRNA vaccines, although these will take time to contribute to sales [6] Group 4: Competitive Landscape - Other companies, such as Pfizer and Moderna, have also entered the RSV vaccine market, with their products gaining traction following initial approvals [7] - GSK's RSV vaccine is approved for high-risk individuals aged 50-59, while competitors have broader approvals for younger high-risk populations [8] Group 5: Financial Performance and Valuation - GSK's stock has increased by 19.2% year-to-date, outperforming the industry, which saw a slight decrease of 0.1% [9] - The company's shares are trading at a forward price/earnings ratio of 8.68, which is lower than the industry average of 14.78 and below its 5-year mean of 10.05 [11] - Earnings estimates for 2025 and 2026 have seen slight upward revisions, indicating potential for future growth [13]